The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Cantargia Receives Patent Approval in China for Antibody Treatment against IL1RAP in Solid Tumors

07-Jan-2018 | Source : Cantargia AB | Visits : 4600
LUND, Sweden - Cantargia AB announced in a press release that the Chinese patent office, the State Intellectual Property Office (SIPO), has formally approved the company’s patent application for IL1RAP as target molecule for antibody therapy of several types of solid tumours. The granted patent has number ZL201280014136.7.

Cantargia is developing antibodies against IL1RAP for treatment of life-threatening diseases. The company’s main project, the immuno-oncology antibody CAN04, is undergoing a clinical phase I/IIa trial focusing on treatment of non-small cell lung cancer and pancreatic cancer. The patent application which has now been approved in China refers to Cantargia’s method of using IL1RAP as target molecule for treatment of several types of solid tumors, including breast cancer, colorectal cancer, lung cancer and malignant melanoma. Cantargia already has the equivalent patent protection in other regions, including Europe, the United States and Japan. The Chinese patent provides protection until 2032.

“Cantargia has strong protection for antibodies against IL1RAP for treatment of cancer in several important territories. The addition of China, which is one of the fastest growing markets for pharmaceuticals, further strengthens our position”, Göran Forsberg, Cantargia’s CEO, says.

Related Articles